By Michael Dabaie
ESSA Pharma Inc. said Wednesday it is in a clinical trial collaboration and supply agreement with Bayer.
ESSA, a clinical-stage pharmaceutical company, said the agreement is to evaluate its lead product candidate, EPI-7386, in combination with Bayer's darolutamide in patients with metastatic castration-resistant prostate cancer.
Under the agreement, Bayer may sponsor and conduct a Phase 1/2 study. ESSA said it will supply EPI-7386 for the trial and will retain all rights to EPI-7386. The clinical study is expected to start in 2021.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
04-28-21 0801ET